» Articles » PMID: 1941754

Amputation and Cisplatin for Treatment of Canine Osteosarcoma

Overview
Date 1991 Jul 1
PMID 1941754
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Seventy-one dogs with histologically confirmed appendicular osteosarcoma were evaluated. Seventeen dogs were treated with amputation and two postoperative [corrected] doses of IV cisplatin given 21 days apart (group 1). Nineteen dogs were treated with IV cisplatin 21 days before amputation, with a second dose given immediately after amputation (group 2). Thirty-five dogs were treated by amputation of the affected limb with no chemotherapy (group 3). The median disease-free interval for group 1 was 226 days, and 177 days for group 2. This was not significantly different. The median survival time was 262 days for group 1, 282 days for group 2 and 119 days for group 3. Group 1 and 2 dogs had survival times that were significantly longer than for dogs in group 3. Two IV courses of cisplatin given before or after amputation appears to improve the survival of dogs with osteosarcoma.

Citing Articles

Antioxidant 1 copper chaperone gene expression and copper levels in dog osteosarcoma patients.

Rivera P, Li W, Bhogal S, Mandell J, Belayneh R, Hankins M Vet Comp Oncol. 2023; 21(3):559-564.

PMID: 37148200 PMC: 11231990. DOI: 10.1111/vco.12903.


Canine osteosarcoma in comparative oncology: Molecular mechanisms through to treatment discovery.

Simpson S, Rizvanov A, Jeyapalan J, de Brot S, Rutland C Front Vet Sci. 2022; 9:965391.

PMID: 36570509 PMC: 9773846. DOI: 10.3389/fvets.2022.965391.


Proteomic Assessment of Extracellular Vesicles from Canine Tissue Explants as a Pipeline to Identify Molecular Targets in Osteosarcoma: PSMD14/Rpn11 as a Proof of Principle.

Luu A, Cadieux M, Wong M, Macdonald R, Jones R, Choi D Int J Mol Sci. 2022; 23(6).

PMID: 35328679 PMC: 8953151. DOI: 10.3390/ijms23063256.


Recent Advances in the Discovery of Biomarkers for Canine Osteosarcoma.

Luu A, Wood G, Viloria-Petit A Front Vet Sci. 2021; 8:734965.

PMID: 34660770 PMC: 8517113. DOI: 10.3389/fvets.2021.734965.


Immunohistochemical Characterisation of GLUT1, MMP3 and NRF2 in Osteosarcoma.

Rutland C, Cockcroft J, Lothion-Roy J, Harris A, Jeyapalan J, Simpson S Front Vet Sci. 2021; 8:704598.

PMID: 34414229 PMC: 8369506. DOI: 10.3389/fvets.2021.704598.